Nuclear factor erythroid 2-related factor 2 (Nrf2) is a vital transcription factor and its induction
is of significant importance for protecting against oxidative damage. Increased levels of …

Abstract Each year, about 5–6 cases out of 100,000 people are diagnosed with primary
malignant brain tumors, of which about 80% are malignant gliomas (MGs). Glioblastoma …

Artesunate, an anti-malarial drug, has been repurposed as an anticancer drug due to its
induction of cell death via reactive oxygen species (ROS) production. However, the …

Targeted therapies and the consequent adoption of “personalized” oncology have achieved
notable successes in some cancers; however, significant problems remain with this …

Cancer is a major health issue worldwide and the global burden of cancer is expected to
reduce the costs of treatment as well as prolong the survival time. One of the promising …

Integrated sequencing strategies have provided a broader understanding of the genomic
landscape and molecular classifications of multiple cancer types and have identified various …

Targeting the redox balance of malignant cells via the delivery of high oxidative stress
unlocks a potential therapeutic strategy against glioblastoma (GBM). We investigated a …

Highlights•De novo anticancer drug discovery is challenging and repurposing in oncology is
a promising field.•Drug repositioning increasingly emerges as faster, cheaper and …

The blood–brain barrier (BBB) is the main bottleneck to prevent some macromolecular
substance entering the cerebral circulation, resulting the failure of chemotherapy in the …

Background The dismal prognosis of glioblastoma (GBM) may be related to the ability of
GBM cells to develop mechanisms of treatment resistance. We designed a protocol called …